Mont. Admin. r. 24.165.522 - ADRENOCORTICO-STEROID AGENTS PROTOCOLS

(1) Clinicians may use adrenocortico-steroid agents as directed by a licensed medical practitioner with prescriptive authority.

(2) Adrenocortico-steroid agents act by diffusing across cell membranes to combine with specific cytoplasmic receptors. The resulting complexes enter the nucleus and bind to DNA, thereby irritating cytoplasmic synthesis of the enzymes responsible for systemic effects of adrenocortico-steroids.

(3) Adrenocortico-steroid agents are indicated for inflammation ( including but not limited to tendonitis, bursitis, arthritis, or myositis), and for antipruritic and vasoconstrictor actions.

(4) Adrenocortico-steroid agents are contraindicated or require special care when used with children, growing adolescents, and pregnant women. Adrenocortico-steroid agents are also contraindicated:

(a) by intolerance to adrenocortico-steroids;

(b) if an infection which is not controlled by antibiotics is present at the treatment site;

(c) for prolonged periods of time;

(d) for large areas; and (e) with occlusive dressings.

(5) The adrenocortico-steroid agents permitted by this rule are:

(a) hydrocortizone cream 10 percent;

(b) dexamethasone sodium phosphate;

(c) triamcinolone acetonide; and

(d) dexamethasone cream.

Notes

Mont. Admin. r. 24.165.522

NEW, 2005 MAR p. 447, Eff. 4/1/05; AMD, 2019 MAR p. 1743, Eff.10/5/2019

AUTH: 37-24-201, 37-24-202, MCA IMP: 37-24-108, 37-24-109, MCA